Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Drug Interaction Study of DS-8500a With Glimepiride or Repaglinide in Healthy Japanese Subjects
jRCT2080223178Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of firuglipel in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Pharmacokinetic interaction between DS-8500a and glimepiride and Pharmacokinetic interaction between DS-8500a and repaglinide.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223178.